Alaunos Therapeutics Statistics Share Statistics Alaunos Therapeutics has 2.19M
shares outstanding. The number of shares has increased by 2.39%
in one year.
Shares Outstanding 2.19M Shares Change (YoY) 2.39% Shares Change (QoQ) 2.39% Owned by Institutions (%) 4.4% Shares Floating 1.57M Failed to Deliver (FTD) Shares 675 FTD / Avg. Volume 0.48%
Short Selling Information The latest short interest is 100.52K, so 6.13% of the outstanding
shares have been sold short.
Short Interest 100.52K Short % of Shares Out 6.13% Short % of Float 6.5% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.65 and the forward
PE ratio is -0.13.
Alaunos Therapeutics's PEG ratio is
0.01.
PE Ratio -0.65 Forward PE -0.13 PS Ratio 305.84 Forward PS 0.1 PB Ratio 1.48 P/FCF Ratio -0.62 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Alaunos Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.98,
with a Debt / Equity ratio of 0.
Current Ratio 3.98 Quick Ratio 3.98 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $10K Profits Per Employee $-4.68M Employee Count 1 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -28.68% in the
last 52 weeks. The beta is -0.83, so Alaunos Therapeutics's
price volatility has been lower than the market average.
Beta -0.83 52-Week Price Change -28.68% 50-Day Moving Average 2.51 200-Day Moving Average 2.47 Relative Strength Index (RSI) 64.59 Average Volume (20 Days) 139,957
Income Statement In the last 12 months, Alaunos Therapeutics had revenue of 10K
and earned -4.68M
in profits. Earnings per share was -2.92.
Revenue 10K Gross Profit 10K Operating Income -4.81M Net Income -4.68M EBITDA -4.68M EBIT -4.68M Earnings Per Share (EPS) -2.92
Full Income Statement Balance Sheet The company has 1.09M in cash and 0 in
debt, giving a net cash position of 1.09M.
Cash & Cash Equivalents 1.09M Total Debt n/a Net Cash n/a Retained Earnings -920.45M Total Assets 4.74M Working Capital 2.66M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.97M
and capital expenditures 0, giving a free cash flow of -4.97M.
Operating Cash Flow -4.97M Capital Expenditures n/a Free Cash Flow -4.97M FCF Per Share -3.1
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -48120% and -46790%.
Gross Margin 100% Operating Margin -48120% Pretax Margin -46790% Profit Margin -46790% EBITDA Margin -46770% EBIT Margin -48120% FCF Margin -49710%
Dividends & Yields TCRT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for TCRT.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 18, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Jul 18, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -272.41 Piotroski F-Score 3
